更新于：2024-09-29
Cilnidipine
西尼地平
更新于：2024-09-29
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 日本 (1995-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看首次获批时间轴
结构
分子式C27H28N2O7 |
InChIKeyKJEBULYHNRNJTE-DHZHZOJOSA-N |
CAS号132203-70-4 |
关联
36
项与 西尼地平 相关的临床试验Comparison of the Efficacy of 24 Hour BP Control of Azelnidipine, Amlodipine and Cilnidipine in Mild to Moderate Essential Hypertension – a Prospective Multi-centric Parallel Arm Real-world Study (AMCILAZ-EH Study) - AMCILAZ-EH Study
Post-approval, case control analyses to assess clinical safety and effectiveness of Azelnidipine and Cilnidipine as initial -addon therapy in management of T2DM with HTN - HYDIAZ
A prospective, single centre, double-blinded, randomised trial with an objective to evaluate the efficacy and safety of an SPC of Cilnidipine (10mg) + Telmisartan (40mg) compared to Telmisartan (40mg) and explore the effects of the SPC on renal outcomes in 200 Indian Diabetic hypertensive patients. The study drug will be Cilacar T (10/40)
100 项与 西尼地平 相关的临床结果
登录后查看更多信息
100 项与 西尼地平 相关的转化医学
登录后查看更多信息
100 项与 西尼地平 相关的专利（医药）
登录后查看更多信息
316
项与 西尼地平 相关的文献（医药）2024-09-01JOURNAL OF PHARMACOLOGICAL SCIENCES
l-DOPA receptor GPR143 inhibits neurite outgrowth via L-type calcium channels in PC12 cells
Article
作者: Inoue, Miyu ; Goshima, Yoshio ; Masukawa, Daiki
The gene product of ocular albinism 1 (OA1)/G-protein-coupled receptor (GPR)143 is a receptor for L-3,4-dihydroxyphenylanine (l-DOPA), the most effective agent for Parkinson's disease. When overexpressed, human wild-type GPR143, but not its mutants, inhibits neurite outgrowth in PC12 cells. We investigated the downstream signaling pathway for GPR143-induced inhibition of neurite outgrowth. Nifedipine restored GPR143-induced neurite outgrowth inhibition to the level of control transfectant but did not affect outgrowth in GPR143-knockdown cells. Cilnidipine and flunarizine also suppressed the GPR143-induced inhibition, but their effects at higher concentrations still occurred even in GPR143-knockdown cells. These results suggest that GPR143 regulates neurite outgrowth via L-type calcium channel(s).
2024-08-01The Journal of the Association of Physicians of India
Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Indian Guideline 2024 by Association of Physicians of India and Indian College of Physicians.
作者: Maheswari, Sanjiv ; Singh, Devendra Prasad ; Chakrabarty, Sekhar ; Pal, Jyotirmoy ; Sahay, Rakesh ; Chatterjee, Nandini ; Ghosh, Sujoy ; Wander, Gurpreet Singh ; Samajdar, Shambo S ; Mathur, Girish ; Tiwaskar, Mangesh ; Panda, Jayanta K ; Murthy, L Sreenivasa
In India and the Southeast Asian population, hypertension and type 2 diabetes mellitus (T2DM) are the leading lifestyle-related diseases, responsible for a majority burden of morbidity and mortality. Multiple population-spanning studies have revealed the staggering prevalence of both diseases in India, and the prevalence of both will only increase further due to factors such as an aging population, rapid urbanization, increased obesity, and sedentary lifestyles. More than 50 percent of hypertensive patients in India are also diagnosed with T2DM, and a detailed management protocol for the same is required, especially when a major portion of the disease is managed at the primary care level. The Association of Physicians of India (API) guidelines for the management of hypertension in patients with T2DM have been formulated based on consultation with leading physicians, cardiologists, diabetologists, and endocrinologists of India and Southeast Asia, keeping in mind the challenges faced by the patients in these countries and the appropriate management protocols that will be beneficial. While standard office-based blood pressure (BP) measurement forms the cornerstone of hypertension diagnosis and demands a uniform methodology to be followed, home blood pressure monitoring (HBPM) is recommended for long-term follow-up with validated devices. Ambulatory blood pressure monitoring (ABPM) offers comprehensive insights crucial for cardiovascular (CV) risk stratification. The complications of diabetic hypertension can span from increased CV risk, heart failure (HF), and renal dysfunction, and nonpharmacological and pharmacological management should be aimed toward not only control of the BP values but also protecting the end organs. While nonpharmacological measures include a focus on nutrition and diet, they also focus on approaches to weight loss, including a novel section covering the benefits of yoga. The guideline also focuses on a novel section of factors influencing CV risk, especially in the Indian population. For the pharmacological management, the guidelines address each of the categories of antihypertensive drugs, emphasizing the significance of combination therapies in the management of diabetic hypertension. In line with leading global guidelines for the management of hypertension in T2DM, for diabetic patients who often struggle with BP management and carry a high CV risk, the recommended dual combination antihypertensive therapy is particularly crucial and should be considered as first-line management therapy. While angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBs) play a highly beneficial role in the management of diabetic hypertension, a combination of ACEi or ARB with dihydropyridine calcium channel blockers (DHP-CCBs) is recommended to reduce the risk of complications and enhance patient adherence. To achieve the target of effective BP control and end-organ protection, it is beneficial and recommended to include newer CCBs (e.g., cilnidipine) in the management protocol in combination with ACEi/ARBs. Combination therapy including ARBs and DHP-CCBs should be preferred over β-blockers and thiazides. Among the CCBs, cilnidipine, a novel molecule, is a more effective and safer option for diabetic hypertensive patients in India. β-blockers should be used if there is a history of myocardial infarction (MI), HF, coronary artery disease (CAD), or stable angina along with the initial hypertensive regimen. The guideline also focuses on the novel reno- and cardioprotective molecules such as finerenone and sodium-glucose cotransporter 2 inhibitors (SGLT2i) and their benefits in the management of diabetic hypertension.
2024-07-30BIOLOGICAL & PHARMACEUTICAL BULLETIN
Anti-atrial Fibrillatory and Cardiorenal Protective Effects of the Combination of Valsartan and Cilnidipine in Dahl Salt-Sensitive Rats
Article
作者: Harada, Eri ; Takahara, Akira ; Sugino, Kazumi
The current study aimed to investigate the anti-atrial fibrillatory (AF) effects of a combination of valsartan and a calcium channel blocker (cilnidipine or amlodipine) in Dahl salt-sensitive (Dahl S) rats. Seven-week-old male Dahl S rats were fed an 8% salt diet. Six weeks later, valsartan (60 mg/kg, Val group), cilnidipine + valsartan (10 + 60 mg/kg, CV group), amlodipine + valsartan (3 + 60 mg/kg, AV group), or vehicle was orally administered daily for 5 weeks. Echocardiography and atrial electrophysiological evaluations were performed on the last day of treatment. Blood pressure in each drug treatment group was lower than in the Vehicle group. The duration of AF induced by atrial burst stimulation was shorter in the Val group (3.2 ± 1.6 s) than in the Vehicle group (11.2 ± 6.0 s), which was further shortened in the CV and AV groups (1.1 ± 0.3 and 1.3 ± 0.3 s, respectively). Left ventricular ejection fraction and left ventricular fractional shortening were greater in the CV and AV groups than those in the Vehicle group. Urinary albumin excretion in the CV group was the lowest among the drug-treated groups. The results collectively suggest that the combination of a calcium channel blocker with valsartan could be useful in terms of its anti-AF action as well as for improving cardiac and renal functions.
100 项与 西尼地平 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 日本 | 1995-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 缺血性卒中 | 临床3期 | 韩国 | 2005-01-01 | |
| 脑卒中 | 临床3期 | 韩国 | 2005-01-01 | |
| 雷诺病 | 临床2期 | 美国 | 2022-07-26 | |
| 硬化肼胝症 | 临床2期 | 美国 | 2022-07-26 | |
| 复杂性局部疼痛综合征 | 临床1期 | 美国 | 2022-01-30 | |
| 神经痛 | 临床1期 | 美国 | 2022-01-30 | |
| 硬皮病相关的手指溃疡 | 临床1期 | 美国 | 2022-01-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 151 | Cilnidipine + 1 AHD | 築鬱廠淵壓積製壓壓繭(齋築選觸獵鏇獵願遞衊) = 窪範鹽鏇鏇範夢構襯餘 醖齋選鑰鑰憲淵積構願 (構築鬱膚獵範廠窪醖範, 6.8 ~ 10.2) 更多 | 积极 | 2024-04-01 | ||
Cilnidipine + 2 AHD | 築鬱廠淵壓積製壓壓繭(齋築選觸獵鏇獵願遞衊) = 簾齋積鬱衊積壓蓋獵鏇 醖齋選鑰鑰憲淵積構願 (構築鬱膚獵範廠窪醖範, 2.1 ~ 8.3) 更多 | ||||||
临床2期 | 27 | 築衊淵製築鑰積醖廠鬱(築築選蓋蓋鏇願壓齋廠) = no safety issues of concern were demonstrated in the first 27 patients 製顧繭窪簾衊憲構鹽簾 (網鏇壓廠鹹範襯窪鑰鹽 ) | 积极 | 2022-07-26 | |||
N/A | - | 鹽簾蓋選餘網膚膚積襯(餘鏇蓋夢網衊積鏇觸築) = 鏇蓋鑰遞獵選襯遞製鹽 齋襯獵願鏇範簾遞構糧 (蓋鹹鹹憲艱範觸鏇壓簾 ) | 积极 | 2017-05-26 | |||
N/A | - | 鏇築廠鹽艱鑰觸壓簾願(築憲鏇鏇壓衊鏇膚構壓) = 鬱襯膚鹹膚網獵網鏇膚 窪遞餘積壓獵廠選壓鏇 (窪鹽衊遞鑰築衊範鏇製, 10.1) | 不佳 | 2017-05-26 | |||
鏇築廠鹽艱鑰觸壓簾願(築憲鏇鏇壓衊鏇膚構壓) = 願襯鹽鏇選壓遞艱齋醖 窪遞餘積壓獵廠選壓鏇 (窪鹽衊遞鑰築衊範鏇製, 15.4) | |||||||
N/A | 70 | Cilnidipine + other CCBs | 廠襯餘鹽夢遞積製製選(壓蓋範選餘糧廠網繭憲) = 廠壓顧憲艱醖遞齋憲壓 淵夢蓋築齋鏇繭鹹憲醖 (範蓋蓋糧襯醖襯鹽鏇網 ) 更多 | 积极 | 2017-05-26 | ||
廠襯餘鹽夢遞積製製選(壓蓋範選餘糧廠網繭憲) = 願獵鹹艱齋範襯鏇繭構 淵夢蓋築齋鏇繭鹹憲醖 (範蓋蓋糧襯醖襯鹽鏇網 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用